GlassScriptPhysician profile
Mona A Parikh
NPI 1639141328
$3,403.40
in general payments reported to CMS, 2019-2025
26 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.20 · 2020: $13.35 · 2021: $417 · 2022: $573 · 2023: $1,008 · 2024: $857 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.73 |
| Education | $158.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $556.16 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $502.32 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $466.73 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $235.15 | 2021-2025 | |
| Exact Sciences Corporation | $234.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $223.80 | 2022-2025 | Veozah |
| Novo Nordisk INC | $161.66 | 2022-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $160.69 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $155.57 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $121.54 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $113.97 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $108.70 | 2022-2025 | Evenity, Prolia, Otezla |
| Endo Pharmaceuticals INC. | $51.68 | 2021-2022 | |
| Lundbeck LLC | $40.68 | 2025 | Rexulti |
| Vbi Vaccine (Delaware) INC. | $36.60 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $35.59 | 2023 | Accrufer |
| Tactile Systems Technology INC | $32.85 | 2025 | Nimbl, Flexitouch Plus |
| Idorsia Pharmaceuticals US INC | $31.95 | 2023-2024 | Quviviq |
| Pfizer INC. | $20.74 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.25 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.18 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $16.67 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $14.02 | 2025 | Zoryve |
| Genentech USA, INC. | $13.35 | 2020 | |
| Horizon Therapeutics Plc | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.